Research Advisory Committee Sample Clauses

Research Advisory Committee. It is agreed that the Parties shall form a Research Advisory Committee for the Research Program. The Research Advisory Committee shall consist of four (4) members, two (2) members to be appointed by each Party. Each Party may appoint or substitute any of its members serving on the Research Advisory Committee by written notice to the other Party. One (1) representative from each Party shall be designated as Team Leader. LLS shall have the right to appoint one (1) of its members to be the chairperson of the Research Advisory Committee to oversee the administration of the Research Advisory Committee. A listing of the initial members of the Research Advisory Committee is included as Exhibit D.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Research Advisory Committee. The Parties shall form a Research Advisory Committee (the “RAC”) for the Research Program which shall serve as a forum for communication and discussion of the activities under the Research Program. The RAC shall be discontinued upon the Research Termination Date or in the event the Research Program otherwise ends. The RAC shall consist of [**] members, [**] members to be appointed by each Party. Each Party may appoint or substitute any of its members serving on the RAC by written notice to the other Party. One (1) representative from each Party shall be designated as “Team Leader” and the Company Team Leader shall serve as the Chairperson of the RAC. Notwithstanding the formation of the RAC or anything in this Agreement to the contrary, Company shall have sole decision-making authority with respect to all aspects of the Research Program, provided that it shall reasonably consider LLS’s recommendations.
Sample 1Sample 2Sample 3
Research Advisory Committee. At termination of the Definitive Agreement, the Parties agree to retain the Research Advisory Committee and the working relationship established. The Parties agree to meet in person or by phone on at least a bi-annual basis to provide updates on the Product development and commercialization efforts of the Product until all contract obligations are completed.
Sample 1Sample 2
Research Advisory Committee. NEI and Diversa shall establish a research advisory committee (the "RAC") comprised of [*****] persons (each, a "Committee Member"), [*****] of whom shall be appointed by NEI and [*****] of whom shall be appointed by Diversa. The RAC may invite other representatives of the Parties, or other individuals as deemed appropriate by the RAC, to participate in meetings of the RAC, as appropriate, provided that no such representative shall have the right to vote as a Committee Member. Each Committee Member, other representative of a Party or other individual invited to participate in a meeting shall, if not already so obligated to a Party, sign a confidentiality undertaking committing such Committee Member, representative or invited individual to fully comply with and respect the Confidentiality obligations of Section 7.
Sample 1Sample 2
Research Advisory Committee. It is agreed that the Parties shall form a Research Advisory Committee for the Research Program (the “RAC”). The RAC shall consist of [**] members, [**] members to be appointed by each Party. Each Party may appoint or substitute any of its members serving on the RAC by written notice to the other Party. One (1) representative from each Party shall be designated as Team Leader. [**] shall have the right to appoint one (1) of its members to be the Chairperson of the Research Advisory Committee to oversee the administration of the RAC. [**] shall have the right to appoint one (1) of its members to be the Secretary of the RAC. A listing of the members of the Research Advisory Committee is attached as Exhibit E, which may be updated from time to time as mutually agreed by the Parties.
Sample 1
Research Advisory Committee. Upon commencement of the Research, AISC will assign a Research Adisory Committee to provide technical oversight and guidance to the Research Project and PI. The Adisory Committee will consist of a limited number of tehnical experts familiar with the topic or topics being investigated. The Advisory Committee cannot add or amend scope to the Research without approval from the AISC Representative in consultation with the PI to determine any cost or schedule impacts. Reports and Data. The PI shall conduct meetings with the AISC Representative and Advisory Committee at milestones in the schedule determined by agreement between the PI and the Advisory Committee. The PI shall provide AISC with scheduled progress reports and a draft Final Report in pdf and Microsoft Word format upon completion of the Research. The draft Final Report shall be reviewed by the AISC Representative and approved if the work is in conformance with the scope and description of the Research set forth in this Agreement. Such review shall be completed within 45 days of submission of the draft Final Report. Within 45 days of the completed review, copies of the Final Report shall be submitted to AISC along with an electronic file containing the report, in a .pdf or MSWord format. The results of the Research shall not be grounds for disapproval of the draft Final Report. The Investigators shall duly consider all reasonable recommendations made by AISC regarding the conduct of the Research. The Investigator will assemble test data in a format that can be read by commercially available software and provide it to AISC with or previous to providing the final report as soon as practicable after each test.
Sample 1
Research Advisory Committee 
Sample 1
AutoNDA by SimpleDocs

Related to Research Advisory Committee

  • Advisory Committee The Settling State shall designate an Opioid Settlement Remediation Advisory Committee (the “Advisory Committee”) to provide input and recommendations regarding remediation spending from that Settling State’s Abatement Accounts Fund. A Settling State may elect to use an existing advisory committee or similar entity (created outside of a State-Subdivision Agreement or Allocation Statute); provided, however, the Advisory Committee or similar entity shall meet the following requirements:

  • Research Committee 2.2.1 Establishment and Functions of RC. ---------------------------------

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Steering Committee The Project Manager shall set up a Steering Committee for the Project, consisting of representatives from the Department, the Contractor, and any other key organisations whom the project will impact on, to be agreed between the parties. The function of the Steering Committee shall be to review the scope and direction of the Project against its aims and objectives, monitor progress and efficiency, and assess, manage and review expected impact and use of the findings from the Project. The Committee shall meet at times and dates agreed by the parties, or in the absence of agreement, specified by the Department. The Contractor’s representatives on the Steering Committee shall report their views on the progress of the Project to the Steering Committee in writing if requested by the Department. The Contractor’s representatives on the Steering Committee shall attend all meetings of the Steering Committee unless otherwise agreed by the Department.

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

  • Operating Committee the Consortium’s managing body, composed of representatives of the Manager and the Contractors, pursuant to Annex XI.

  • Advisory Board (a) The Managing Member may establish an Advisory Board comprised of members of the Managing Member’s expert network and external advisors. The Advisory Board will be available to provide guidance to the Managing Member on the strategy and progress of the Company. Additionally, the Advisory Board may: (i) be consulted with by the Managing Member in connection with the acquisition and disposal of a Series Asset, (ii) conduct an annual review of the Company’s acquisition policy, (iii) provide guidance with respect to, material conflicts arising or that are reasonably likely to arise with the Managing Member, on the one hand, and the Company, a Series or the Economic Members, on the other hand, or the Company or a Series, on the one hand, and another Series, on the other hand, (iv) approve any material transaction between the Company or a Series and the Managing Member or any of its Affiliates, another Series or an Economic Member (other than the purchase of interests in such Series), (v) provide guidance with respect to the appropriate levels of annual fleet level insurance costs and maintenance costs specific to each individual Series Asset, and review fees, expenses, assets, revenues and availability of funds for distribution with respect to each Series on an annual basis and (vi) approve any service providers appointed by the Managing Member in respect of the Series Assets.

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.